Cardiology · Beta-blocker
The FDA's approval of Micro Labs' ANDA217238 for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could significantly impact pricing and market share dynamics. Pharma companies with existing propranolol products need to reassess their strategies in light of this increased competition.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/30/2026, 12:30:27 PM
Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.
The FDA's approval of Micro Labs' ANDA217238 for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could significantly impact pricing and market share dynamics. Pharma companies with existing propranolol products need to reassess their strategies in light of this increased competition. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 7 ranked evidence items (1 high-relevance).
Portfolio teams should assess the impact of this approval on pricing and market share for existing propranolol products. The strongest clinical anchor is Cardiology Biobank Registry (ClinicalTrials.gov), sub-indication match (cardiology). In cardiology, 6 regulatory and 0 competitive items passed relevance filtering for Micro Labs.
The most relevant competitive pressure comes from This approval allows Micro Labs to market a generic version of Propranolol Hydrochloride, increasing competition in the beta-blocker market..
Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). The approval indicates compliance with FDA standards, but does not introduce new regulatory challenges for existing products.
Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceFDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAmedium relevance
Entity match (micro labs); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAmedium relevance
Entity match (propranolol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAmedium relevance
Entity match (propranolol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceCardiology Biobank Registry
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View sourceMetformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceMicroneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceVivistim Registry for Paired VNS Therapy (GRASP)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFDA Drug Trials Snapshot: YARTEMLEA Approved for TA-TMA
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceComparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Micro Labs' ANDA217238 for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could significantly impact pricing and market share dynamics. Pharma companies with existing propranolol products need to reassess their strategies in light of this increased competition.
The entry of a generic version may lead to price reductions and erosion of market share for branded propranolol products, affecting revenue streams.
The approval indicates compliance with FDA standards, but does not introduce new regulatory challenges for existing products.
Monitor market entry date and pricing strategies of Micro Labs post-approval.
Track for follow-up milestones; no immediate action required.